Yue Xu

Yue Xu

Auto-generated profile, based on publicly available information

Yue Xu

Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin 150040, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in Sustainable Materials and Technologies
Verified
Journal Article
Closed access
CDChunlin Du
Chunlin Du
YXYue Xu
Yue Xu
CYChentao Yan
Chentao Yan
WZWenjia Zhang
Wenjia Zhang
HHHaojie Hu
Haojie Hu
LLLubin Liu
Lubin Liu

1 September 2021 in Development
Verified
Journal Article
Closed access
PDF file
MWMei Wu
Mei Wu
YXYue Xu
Yue Xu
JLJing Li
Jing Li
JLJunwei Lian
Junwei Lian
QCQi Chen
Qi Chen
YZYiyue Zhang
Yiyue Zhang
Neutrophils are the most abundant vertebrate leukocytes and they are essential to host defense. Despite extensive investigation, the molecular network controlling neutrophil differentiation remains incompletely understood. GFI1 is associated with several myeloid disorders, but its role and the role of its co-regulators in granulopoiesis and pathogenesis are far from clear. Here, we demonstrate that zebrafish gfi1aa deficiency induces excessive neutrophil progenitor proliferation, accumulation of immature neutrophils from the embryonic stage, and some phenotypes similar to myelodysplasia syndrome in adulthood. Both genetic and epigenetic analyses demonstrate that immature neutrophil accumulation in gfi1aa-deficient mutants is due to upregulation of cebpa transcription. Increased transcription was associated with Lsd1-altered H3K4 methylation of the cebpa regulatory region. Taken together, our results demonstrate that Gfi1aa, Lsd1 and cebpa form a regulatory network that controls neutrophil development, providing a disease progression-traceable model for myelodysplasia syndrome. Use of this model could provide new insights into the molecular mechanisms underlying GFI1-related myeloid disorders as well as a means by which to develop targeted therapeutic approaches for treatment.